Jinwoo Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jinwoo Hong has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Chae-Ok Yun
Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea
11 shared publications A-Rum Yoon
Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, Republic of Korea
4 shared publicationsDayananda Kasala
Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, Republic of Korea
4 shared publicationsEonju Oh
Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Republic of Korea
4 shared publicationsHyo Min Ahn
Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, 133-791, Seoul, Republic of Korea
3 shared publicationsSoo-Jung Jung
Department of Bioengineering, College of Engineering, Hanyang University, South Korea
3 shared publications
Latest Publications
- Open Access
- 30 March 2018
- Published by The Society of Korean Medicine in Journal of Korean Medicine
- Vol. 39 (1) , 75-85
Case Report on Long Term Survival of Glioblastoma Patient Treated with Integrative Medicine
- 30 March 2018
- Published by The Society of Korean Medicine in Journal of Korean Medicine
- Vol. 39 (1) , 75-85
Open AccessCase Report on Long Term Survival of Glioblastoma Patient Treated with Integrative Medicine
- 15 January 2018
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 18 (2) , 139-152
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancerspecific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.
- 15 January 2018
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 18 (2) , 139-152
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancerspecific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors.
- 1 June 2017
- Published by Elsevier in Cancer Letters
- Vol. 396, 155-166
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer
- 1 June 2017
- Published by Elsevier in Cancer Letters
- Vol. 396, 155-166
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer
- Open Access
- 10 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (3) , 4730-4746
Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
- 10 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (3) , 4730-4746
Open AccessOncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
- 7 November 2016
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 10 (11) , 10533-10543
Mild Hyperthermia Induced by Gold Nanorod-Mediated Plasmonic Photothermal Therapy Enhances Transduction and Replication of Oncolytic Adenoviral Gene Delivery
Oncolytic adenovirus (Ad) is a promising candidate for cancer gene therapy. However, as a monotherapy it has shown insufficient therapeutic efficacy in clinical trials. In this work we demonstrate that gold nanorod (GNR)-mediated mild hyperthermia enhances the cellular uptake and consequent gene expression of oncolytic Ad to head and neck tumor cells. We examined the combination of oncolytic Ad expressing vascular endothelial growth factor (VEGF) promoter-targeted artificial transcriptional repressor zinc-finger protein and GNR-mediated mild hyperthermia to improve antitumor effect. The in vitro mechanisms of increased transduction in the presence and absence of hyperthermia were explored followed by evaluation of efficacy of this combination strategy in an animal model. Exposure to optimized hyperthermia conditions improved endocytosis of oncolytic Ad, transgene expression, viral replication, and subsequent cytolysis of head and neck cancer cells. GNR-mediated plasmonic photothermal therapy resulted in precise control of tumor temperature and induction of mild hyperthermia. Combination of oncolytic Ad and GNRs resulted in potent tumor growth inhibition of head and neck tumor.
- 7 November 2016
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 10 (11) , 10533-10543
Mild Hyperthermia Induced by Gold Nanorod-Mediated Plasmonic Photothermal Therapy Enhances Transduction and Replication of Oncolytic Adenoviral Gene Delivery
Oncolytic adenovirus (Ad) is a promising candidate for cancer gene therapy. However, as a monotherapy it has shown insufficient therapeutic efficacy in clinical trials. In this work we demonstrate that gold nanorod (GNR)-mediated mild hyperthermia enhances the cellular uptake and consequent gene expression of oncolytic Ad to head and neck tumor cells. We examined the combination of oncolytic Ad expressing vascular endothelial growth factor (VEGF) promoter-targeted artificial transcriptional repressor zinc-finger protein and GNR-mediated mild hyperthermia to improve antitumor effect. The in vitro mechanisms of increased transduction in the presence and absence of hyperthermia were explored followed by evaluation of efficacy of this combination strategy in an animal model. Exposure to optimized hyperthermia conditions improved endocytosis of oncolytic Ad, transgene expression, viral replication, and subsequent cytolysis of head and neck cancer cells. GNR-mediated plasmonic photothermal therapy resulted in precise control of tumor temperature and induction of mild hyperthermia. Combination of oncolytic Ad and GNRs resulted in potent tumor growth inhibition of head and neck tumor.
- Open Access
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (51) , 84965-84980
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (51) , 84965-84980
Open AccessOncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
- 27 June 2016
- Published by Taylor & Francis in Nanomedicine
- Vol. 11 (13) , 1689-1713
Evolving Lessons on Nanomaterial-Coated Viral Vectors for Local and Systemic Gene Therapy
Viral vectors are promising gene carriers for cancer therapy. However, virus-mediated gene therapies have demonstrated insufficient therapeutic efficacy in clinical trials due to rapid dissemination to nontarget tissues and to the immunogenicity of viral vectors, resulting in poor retention at the disease locus and induction of adverse inflammatory responses in patients. Further, the limited tropism of viral vectors prevents efficient gene delivery to target tissues. In this regard, modification of the viral surface with nanomaterials is a promising strategy to augment vector accumulation at the target tissue, circumvent the host immune response, and avoid nonspecific interactions with the reticuloendothelial system or serum complement. In the present review, we discuss various chemical modification strategies to enhance the therapeutic efficacy of viral vectors delivered either locally or systemically. We conclude by highlighting the salient features of various nanomaterial-coated viral vectors and their...
- 27 June 2016
- Published by Taylor & Francis in Nanomedicine
- Vol. 11 (13) , 1689-1713
Evolving Lessons on Nanomaterial-Coated Viral Vectors for Local and Systemic Gene Therapy
Viral vectors are promising gene carriers for cancer therapy. However, virus-mediated gene therapies have demonstrated insufficient therapeutic efficacy in clinical trials due to rapid dissemination to nontarget tissues and to the immunogenicity of viral vectors, resulting in poor retention at the disease locus and induction of adverse inflammatory responses in patients. Further, the limited tropism of viral vectors prevents efficient gene delivery to target tissues. In this regard, modification of the viral surface with nanomaterials is a promising strategy to augment vector accumulation at the target tissue, circumvent the host immune response, and avoid nonspecific interactions with the reticuloendothelial system or serum complement. In the present review, we discuss various chemical modification strategies to enhance the therapeutic efficacy of viral vectors delivered either locally or systemically. We conclude by highlighting the salient features of various nanomaterial-coated viral vectors and their...
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S47
112. Potent Antifibrotic Effect on Human Dermal Fibroblasts and Keloid Spheroids by Adenovirus-Mediated Inhibition of Wnt and TGF-β Signaling
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S47
Open Access112. Potent Antifibrotic Effect on Human Dermal Fibroblasts and Keloid Spheroids by Adenovirus-Mediated Inhibition of Wnt and TGF-β Signaling